In the second stage, we tested the pairwise associations between transformed CSF biomarkers and the methylation residuals from stage 1, adjusting for diagnosis of AD and the APOE4 allele counts, both of which are potential confounders of the CSF biomarker-methylation associations. The gene discussed is APOE; the disease is Alzheimer disease.